Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 0.000000
forwardPE 28.675165
debtToEquity 5.698000
earningsGrowth 0.179000
revenueGrowth 0.200000
grossMargins 0.762670
operatingMargins 0.246380
trailingEps 81.290000
forwardEps 98.691670

AJANTPHARM's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
AJANTPHARM's positive earnings and revenue growth reflect an optimistic outlook for the company's future. The growth in these key areas indicates that AJANTPHARM is expected to continue expanding its business and boosting its financial performance in the coming periods.
AJANTPHARM's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
AJANTPHARM's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in AJANTPHARM's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

AJANTPHARM's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


6 sell transactions of Ajanta Pharma Limited were recorded, with market price hovering near 2686.9166666666665.During the period under consideration, there were no sell transactions.More buys than sells near the current price levels of AJANTPHARM might signal a favorable outlook for the stock. Investors seem to be showing confidence by purchasing more, potentially expecting positive future performance.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts have shown a buy bias for Ajanta Pharma Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Ajanta Pharma Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.